


Toxicology study results in NHP validated improved PK and safety profile of CAPTN-3 masking design, revealing an extended therapeutic window
in Jun 11, 2026
Presented at the EACR 2026 Congress, June, 2026

CAPTN-3 unique design demonstrated by 2 novel platform trispecific T Cell engagers
in Dec 11, 2025
Presented at the ESMO Immuno-Oncology Congress 2025, December, 2025

CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers
in Jun 23, 2025
Presented at the EACR 2025 Congress, June, 2025

Final results of the randomized Phase 2 of CM24 in pancreatic cancer: Improved outcomes and significant efficacy in a serum biomarker-enriched subgroup
in May 01, 2025
Presented at the AACR annual meeting, April 2025
APC-loss as a potential biomarker for NT219 treatment in colorectal cancer
in Apr 29, 2025
Presented at the AACR annual meeting, April 2025
NT219 overcomes immune evasion mechanisms in head and neck squamous cell carcinoma (HNSCC)
in Apr 29, 2025
Presented at the AACR annual meeting, April 2025
